Advanced Search

Tyrosine Kinase Stocks List

Symbol Grade Name % Change
EXEL B Exelixis, Inc. -3.46
EYPT D EyePoint Pharmaceuticals, Inc. -5.05
RIGL C Rigel Pharmaceuticals, Inc. -5.26
PBYI D Puma Biotechnology Inc -5.39
KIN D Kindred Biosciences, Inc. -2.96
BPMC F Blueprint Medicines Corporation -2.49
KALA D Kala Pharmaceuticals, Inc. -13.32
COGT F Cogent Biosciences, Inc. -3.71
BBIO B BridgeBio Pharma, Inc. -3.14
RLAY F Relay Therapeutics, Inc. -2.26
NRIX F Nurix Therapeutics, Inc. -6.16
KRON F Kronos Bio, Inc. -0.07
ANGN D Angion Biomedica Corp. 0.00
View As Page of Charts
Related Industries: Biotechnology Other
Related Stock Lists: Cancer Biopharmaceutical Protein Kinase Inhibitor Biotechnology Enzymes Tyrosine Kinase Receptors Fibroblast Growth Factor Receptor Gastrointestinal Inflammation Medicine Ophthalmic Receptor Tyrosine Kinase Autoimmune Disease Autoimmune Diseases Bruton Chemical Compounds Daiichi Sankyo Eye Gastrointestinal Stromal Tumor Glucocorticoids

Related ETFs - A few ETFs which own one or more of the above listed Tyrosine Kinase stocks.

Symbol Grade Name Weight
IDNA D iShares Genomics Immunology and Healthcare ETF 7.46
IBBJ C Defiance Nasdaq Junior Biotechnology ETF 5.93
PBE C PowerShares Dynamic Biotech & Genome 4.58
LABD F Direxion Daily S&P Biotech Bear 3X Shares 4.46
XBI D SPDR Series Trust SPDR S&P Biotech ETF 3.98
View all Tyrosine Kinase related ETFs...
Compare ETFs
  • Compare IBBJ to PBE
  • Compare IBBJ to XBI
  • Compare IDNA to IBBJ

    • Recent Signals

    Date Stock Signal Type
    2021-02-24 BBIO 50 DMA Support Bullish
    2021-02-24 BPMC 20 DMA Resistance Bearish
    2021-02-24 EXEL NR7 Range Contraction
    2021-02-24 EXEL Bollinger Band Squeeze Range Contraction
    2021-02-24 EXEL Crossed Above 200 DMA Bullish
    2021-02-24 EXEL Crossed Above 20 DMA Bullish
    2021-02-24 EYPT Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
    2021-02-24 KALA NR7 Range Contraction
    2021-02-24 KALA 200 DMA Resistance Bearish
    2021-02-24 KALA 20 DMA Support Bullish
    2021-02-24 KIN Fell Below 50 DMA Bearish
    2021-02-24 KRON 20 DMA Support Bullish
    2021-02-24 NRIX 20 DMA Resistance Bearish
    2021-02-24 NRIX 50 DMA Resistance Bearish
    2021-02-24 NRIX Shooting Star Candlestick Bearish
    2021-02-24 NRIX Bollinger Band Squeeze Range Contraction
    2021-02-24 NRIX Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
    2021-02-24 PBYI MACD Bearish Centerline Cross Bearish
    2021-02-24 PBYI Stochastic Buy Signal Bullish
    2021-02-24 PBYI Bullish Engulfing Bullish
    2021-02-24 RIGL Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
    2021-02-24 RIGL 1,2,3 Pullback Bullish Bullish Swing Setup
    2021-02-24 RIGL Crossed Above 20 DMA Bullish

    Recent News for Tyrosine Kinase Stocks

    Date Stock Title
    Feb 25 PBYI Puma Biotechnology EPS misses by $0.05, misses on revenue
    Feb 25 PBYI Puma Biotechnology and Pierre Fabre amend NERLYNX license agreement
    Feb 25 PBYI Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China
    Feb 25 PBYI Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
    Feb 25 EXEL Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in March
    Feb 25 KIN Kindred Biosciences Submits Efficacy Data For KIND-030 As Prophylactic Option In US
    Feb 25 EXEL Exelixis' Cabozantinib Gets Breakthrough Therapy Status In Differentiated Thyroid Cancer
    Feb 25 EXEL Exelixis' CABOMETYX wins FDA's breakthrough therapy status
    Feb 25 KIN Kindred submits efficacy data to support KIND-030 prophylactic indication approval
    Feb 25 KIN Kindred Biosciences Announces Submission of Parvovirus Monoclonal Antibody Data for Prophylactic Indication
    Feb 25 KRON Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers
    Feb 25 EXEL Exelixis Announces Breakthrough Therapy Designation Granted to Cabozantinib for the Treatment of Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
    Feb 25 BBIO BridgeBio Pharma EPS misses by $0.16, misses on revenue
    Feb 25 BBIO BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update
    Feb 25 KALA Kala Pharmaceuticals EPS misses by $0.09, misses on revenue
    Feb 25 EYPT EyePoint Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
    Feb 25 KALA Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
    Feb 25 KIN Is Kindred Biosciences (NASDAQ:KIN) Using Too Much Debt?
    Feb 24 PBYI Puma Biotechnology Q4 2020 Earnings Preview
    Feb 24 BBIO BridgeBio Pharma To Announce Proof-Of-Concept Data from ADH1 at the Endocrine Society’s 2021 Annual Meeting
    Related Industries: Biotechnology Other
    Related Stock Lists: Cancer Biopharmaceutical Protein Kinase Inhibitor Biotechnology Enzymes Tyrosine Kinase Receptors Fibroblast Growth Factor Receptor Gastrointestinal Inflammation Medicine Ophthalmic Receptor Tyrosine Kinase Autoimmune Disease Autoimmune Diseases Bruton Chemical Compounds Daiichi Sankyo Eye Gastrointestinal Stromal Tumor Glucocorticoids

    Browse All Tags